Brought to you by 
CSL buys Talecris for $3.1bn in cash and debt; withdrawn
Aug 2008
Executive Summary
Australian hemostasis therapeutics developer CSL has agreed to pay $3.1bn--$1.9bn in cash and $1.2bn in net debt--to acquire privately held Talecris Biotherapeutics (critical care treatments in the areas of immunology, hemostasis, and pulmonology).
Deal Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Acquisition of Private Biotech
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com